In the present work, we show that the nrf2 pathway is dysregulated in patients and in mice with SSc, and report a more severe form of SSc in Nrf2−/− mice along with the therapeutic properties of the nrf2 agonist DMF. This evidence concerns the gene NFE2L2 and systemic sclerosis.